WJPMR, 2026, 12(7), 189-208

Research Article

Impact Factor: 7.555

WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.wjpmr.com

ISSN (O): 2455-3301

ISSN (P): 3051-2557

Coden USA: WJPMBB

CARDIAC BIOMARKERS

Seema D. Jogad*[1], Megha S. Bora[2], Sayali S. Shelar[3], Madhuri S. Harde[4]

India.

***Corresponding Author: Seema D. Jogad**

India. **DOI:** https://doi.org/10.5281/zenodo.20962593

How to cite this Article: Seema D. Jogad*[1], Megha S. Bora[2], Sayali S. Shelar[3], Madhuri S. Harde[4]. (2026). Cardiac Biomarkers. World Journal of Pharmaceutical and Medical Research, 12(7), 189-208.

Article Received on 15/05/2026 **Article Revised on 05/06/2026** **Article Published on 01/07/2026**

ABSTRACT

Cardiovascular diseases are important factor to cause mortality and disability globally. High blood pressure, hyperglycemia, smoking and hpercholestremia are responsible to cause cardiovascular disease. Cardiac biomarkers are specific substances released from the heart muscles when it is get damaged as a result of myocardial infraction. Biomarkers are use to identify the presence, reasons and extent of damage of cardiac tissue, they enhances the risk stratification measurement for cardiovascular disease. Various biomarkers are explained in this review with their roles, troponin are the current standard for diagnosis of myocardial infraction, pregnancy associated plasma proteins-A (PAPP-A) is a capable biomarker for risk identification in cardiac stress, matrix metalloproteinase are responsible for plague repture, it is estimated that myloperoxidase ismain contributor within the development and rupture of plague, H-FABP, soluble suppression of tumorigenicity an miRNA has probable to improve diagnosis and treatment of patients suspect of an adverse cardiac events, MR-proADM is important marker for the patient who have atherosclerotic plague, heart failure and cardiovascular disease.

INTRODUCTION

In 2002, cardiovascular diseases contributed to approximately a 3rd of entire globe deaths, whereas by the year 2020. It is expected that cardiovascular diseases will become the important factor to cause mortality and disability globally.[1] Traditional hazard issues for cardiovascular diseases are high blood pressure, hyperglycemia, smoke, and hypercholestremia, gave rise to advancement to therapy. Though adequate to 20% of volunteers with coronary illness include no conventional risk causes, and 40% include only one.[2] In this review we are going to discuss biomarkers to enhance the risk stratification measurement for cardiovascular diseases. Biomarkers refers to subcategory of experimental and regenerative characteristics of biologically active substances.

The NIH consortium in 2001 distinct biomarkers as "a individuality that is impartially deliberate and assess as an indication of usual biological, pathogenic process, or pharmacologic answers of a beneficial interventions"[3]. Biomarkers are measured on biotic specimens like hemoglobin, urine or tissue test.



Information from genomic and proteomics that distinguish fit from ill condition lead to biomarker detection and recognition.[4]

Biomarkers can demonstrate an assortment of wellbeing or illness. Attributes including the level or kind of introduction to an:

A) Natural Factor,
B) Hereditary Vulnerability,
C) Genetic Response to Exposure,
D) Markers of Subclinical and Clinical Infection,
E) Pointers of Reaction to Treatment.

In this way, a simplistic approach to consider biomarkers is:

I) Pointers of infection characteristics (Hazard factor or danger marker).

II) Infection state (Animal or volunteer trial).

III) Infection rate (Development of disease).[3]

Appropriately, Biological markers can be named as BIOLOGICAL MARKERS[5]



Fig. 1: Ideal characteristics of biomarkers and their types.[6]

Biomarkers also serve as surrogate endpoints.[5] Surrogate end points are solitary be able to utilized as a result in scientific preliminaries to assess security and viability of treatments in lieu of estimination of the genuine result of interest. The hidden rule is that changes in the surrogate end point track immediately with change in the result of interest.[7-9]

Feature of ideal biomarkers-General principles: overall expectations of cardiovascular biomarkers is to improves the capability of the physician to optimally handle the patient. a biomarker can assist to individualize the patient by means of an acute myocardial infraction(MI) since those with unstable angina (e.g.- troponin I or T), acute pulmonary embolism (e.g.- D dimer or ventilation perfusion examination), or an aortic dissection (e.g- transesophagal echocardiogram) to facilate targeted management.



Despite of the rationale of its utilization, a biomarker should have following properties:

- Scientific value (simply if it is correct)
- Reproducibility (Obtained in standardized manner)
- Satisfactory to the patient
- Simple to interpret by physicians
- Should have elevated sensitivity and elevated specificity
- Should explains a reasonable proportion of outcomes.[10-18]

In this review, a methodical survey on pubMed, web of science and scopus is done using the keywords "Biomarkers, cardiovascular disease, ACS, CAD, myocardial infraction or heart failure". An imerging biomarkers or those on the horizontal into the group of myocardial necrosis' inflammation' plague unsteadiness, platelet activation, myocardial stress, neurohormonal stimulation and expelled those conventional pro inflammatory molecule such as IL-6, TNF-α and VCAM-1. The noval biological markers representing different pathophysiological process related with CVD were reviewed in the figure.



Fig. 2: Biomarkers of heart failure according to pathophysiological processes.[6]




Plague Instability
PAPP-A:
Capable biomarker for risk identification in acute cardiac stress.
MPO:
Prospective examination addresses the function of myloperoxidase as a important flowing biomarker of cardiovascular disease.
MMPs:
MMP-2,8,9 has been identified as protease which are responsible for plague repture and experimental events.
Plague Activation
Lp-PLA2:
Increased in concentration of lipoprotein associated phospholipase A2 indicated relationship with higher CVD risk. Experimental usefulness is unclear.
s-PLA2:
Higher circulating s-PLA2-IIA and s-PLA2 concentration are connected with increased cardiovascular events.
s-CD40L :
Prognostic importance for detecting cardiovascular events.
Inflammation
Hs-CRP:
Hs-CRP that identifies the decreased level of reactive protein might help to identify high risk patients.
GDF-15:
Experimental studies shows that GDF-15 is important detector of CVD and responsible factors of death. Probable means for risk stratisfictation.
Fibrinogen:
Prospective examination hold up that incresased fibrinogen concentration are connected with elevated risk of CVD.
Uric acid:
Trials shows that uric acid have independent positive relationship with cardiovascular death.
Neurohormal activation
Coceptin:
Coceptin might Predict cardiovascular disease development and CAD.
MR-proADM:
Important biomarker for risk identificationfor the patient who have atherosclerotic plague and HF and CAD.



Fig. 3: Various Cardiac Biomarkers and their impression.

1. Biomarkers of cardiac injury

CARDIAC TROPONIN

Troponin may be a advanced of 3 round contracted regulative proteins (troponin T, I, and C) to dwell into customary stretches within the meager fiber of skeletal muscle so as to restrains compression by clogging the cooperation of simple protein and globulin viscus.[19] Troponin I (cTnI) and T (cTnT) are proteins that are exceptional near the heart and are specific and delicate biological markers of heart muscle injury.[20] The cTnT and cTnI are various in skeletal and cardiovascular muscle, that takes into thought their utilization as a heart specific biomarker. The troponin C found in kind two strands of the striated muscle and therefore the CV muscle are indistinguishable; accordingly, it's difficult to be used as a heart specific biomarker. Inside intense heart muscle dead tissue (AMI), cTnI and cTnT are delivered from death heart muscle as each unstained proteins what is more, debasement things. the placement of cTn in peripheral blood shows and measures cardiomyocyte damage. vas troponins are additional touchy and specific markers of cardiomyocyte injury than aminoalkanoic acid enzyme (CK), its MB isoenzyme (CK-MB) and haemoprotein. within the event that the clinical presentation is viable with heart muscle ischaemia, a dynamic elevation of vas troponin over the 99th score of healthy folks shows AMI.[21] But, a major limitation of normal cTn measures is their low affectability at the hour of AMI introduction, that is attributable to a late increment in circling concentration and needs serial sampling for 6–9 h in an exceedingly hefty variety of patients.

HIGH SENSITIVITY CARDIAC TROPONIN

Innovative advances have prompted a modification in cTn assays and have enhanced the capacity to distinguish as well as measure heart tissue injury.[20] Newly, a more current generation of troponin examination with higher sensitivity have become accessible. The development of these hs-cTn assays has changed the function of cTn as of a biological marker utilized uniquely in the intense finding of sickness to a biological marker so as to evaluates progressing heart tissue injury in steady patients and still apparently sound populaces. sensitive cTn and hs-cTn measures have two unique highlights from regular cTn measures: (1) discovery of cTn in a considerable amount of sound people as well as (2) a more precise meaning of "ordinary level" (the ninetynine percentile) with a more exact assay.[22] In patients with AMI, levels of heart troponin rise rapidly, normally inside 1 h if utilizing high-affectability measures after manifestation beginning, and they stay raised for a variable time of time.[9] Information from a few huge multicenter studies have reliably demonstrated that delicate cTn and hs-cTn assays increase the accurateness of AMI finding during introduction to the crisis section.[24,25] A new examination further expands the relationship between high-sensitivity troponin and 5-year results among patients with hyperglycemia and steady coronary corridor illness (CAD).

This examination demonstrated a tough, predictable relationship linking the pattern groupings of circling cTnT and the risk of every reason of casualty, myocardial infraction (MI), stroke, and heart failure (HF) in patients with both sort 2 diabetes and stable CAD. These outcomes recommend that utilizing the hs-cTn examine for patients with diabetes and CAD is an excellent instrument for hazard stratification.[26]

HEART TYPE UNSATURATED FAT RESTRICTING PROTEINS (H-FABP)

Cytoplasmic FABP characterize to a group of transport proteins that takes into consideration the carrying of unsaturated fats throughout the layers. FABP is tissue specific in this manner.



Fig. 4: Types of unsaturated fat restricting proteins.[27]

H-FABP may be a low mass macromolecule contained 132 amino acids and is engaged with cardiac muscle unsaturated fat digestion. It is originate in plentitude inside cardiac tissues and in addition in very little amounts within the cerebrum, kidney, and skeletal tissue, and its concentration will increment attributable to intense ischemic strokes and extreme exercise. H-FABP is quickly delivered in the cytoplasm from the showtime in AMI.

Ongoing investigations have indicated that H-FABP is also superior to or enhances troponin within the early finding of intense coronary disorder (ACS), as incontestible by ROC analyses.[28,29] Kabekkodu, et al[30] determined that amongst AMI patients introducing within four h of indication starting, the affectability of H-FABP was sixty percent, that is basically over that of cTnI (18.8%) and CK-MB (12.5%). In any case, the clarity was because it were 23.53%, that isn't the maximum amount as that of cTnI (66.67%) and CK-MB (100%). throughout 4–12 h of indication starting, the sensitivity of H-FABP was 96.96%, much similar to that of cTnI (90.9%) and CK-MB (77.3%) and therefore the quality was hour within the 4–12 h gathering, like that of cTnI (half) and CK-MB (half). Moreover, the H-FABP level was multiplied in relationship with a lot of outstanding quantities of vas hazard issues Associate in Nursing was an autonomous danger factor for every-cause and CVD death. Fitly, H-FABP may well be a valuable marker for the first characteristic proof of elevated danger patients within the general population.[31]

2. BIOMARKERS OF PLAGUE INSTABILITY

PRGNANCY ASSOCIATED PLASMA PROTEINS (PAPP-A)

PAPP-A could be a Zn strap matrix metalloproteinase that fit in to metazincin cluster of metalloproteinases. at first known in a pregnant lady, it is formed in placenta. PAPP-A causes the activation of insulin-derived growth factor-1(IGF-1), this IGF-1 induces the inflammation and lipide uptake results into pathology and plague instability.[32] a pair of initial experimental studies counsel that the PAPP-A concentration is said with recurring ischemic events in patients with assumed acute coronary syndrome, freelance of Tnl.[33,34] later on some experimental studies have demonstrate that increased concentration of PAPP-A in patient with steady or unsteady CAD are connected with elevated risk of CVD events.[35,36] In potential examination, found a necessary association among PAPP-A and CVD mortality or recurring ischemia events in 3782 volunteers with ACS in conjugation with a current sensitive assay for cTnI. Consequently, current PAPP-A could be a capable biological marker for risk stratification of acute coronary syndrome. Newly, a 3-vessel virtual microscopic anatomy (VH)-intravascular ultrasound (IVUS) examination established for the primary time, that accumulated PAPP-A concentration are connected with higher 3-vessel skinny cap fibroatheroma hassle within the patient with CAD,[37,38] therefore PAPP-A could be a helpful biomarker to observe accumulated coronary thin-cap fibroatheroma load and plague instability.

MYELOPEROXIDASE (MPO)

MPO, a component of the protoheme oxidase family, is formed by polymorphonuclear leukocytes, neutrophils, and monocytes and discharged in provocative circumstances. Myeloperoxidase is articulated via macrophages ready of stimulating MMP and suppressing TIMP, and it stimulates denseness compound protein (LDL) oxidisation through acid production stimulates oxidisation of ApoA-I, and reduces steroid alcohol discharge ability.[39] Myeloperoxidase is estimated to be a main contributor within the development and bursting of plaque.[40] Studies shows that MPO concentration have a substantial opposite association with concentration of paraoxonase-1 sure to high density compound protein (HDL), significantly in patients with steady and unsteady

angina, that indicate a pair involving pro-oxidants and anti-oxidants could contribute to the progression of coronary plaque instability. Associate relationship among MPO concentation and CAD risk was initial reportable in 2001.[41] In further perspective trial,[42] observes the link of MPO with the chance of CAD development in associate at first healthy volunteers within the European Prospective examination into Cancer and Nutrition (EPIC)-Norfolk study. Succeeding prospective and cross-sectional assessment mention the function of MPO as a current inflammatory biomarker in acute coronary syndrome,[43] heart failure,[44] and coronary artery disease.[45] Within the CAPTURE experimental study.[46] Investigated the prognostic details of current MPO concentrations in 1090 patients with ACS and examines the chance stratifications of those patients by biomarker comination actions. In distinction, Nicholls, et al.[47] established that MPO concentrations were prognostic of cardiovascular events up to sixteen h once pain. It appears that, in spite of the initial progression of blood corpuscle activation and MPO discharge, it's solely probable to use MPO for risk stratification within the early part from the onset of pain. newly, an outsized long study (Ludwigshafen Risk and vas Health) investigated 3036 volunteers established that MPO concentrations however not genetic variants at the MPO locus were one by one connected with risk for total and cardiovascular mortality in CAD. conjointly, gift conclusion don't give proof for a right away relation of MPO within the risk of adverse clinical outcomes, therefore the operate of MPO in determining patients in danger for MI is partial. Studies significantly work the particular operate of MPO are still required, and regular measuring of this biomarker isn't prompt in any scientific settings.

MATRIX METALOPROTEINASE (MMPs)

MMPs are a group of endopeptidases that are concealed by a range of inflammatory and tumour cells as zymogens and are later on stimulated by proteinases. MMPs have completely different functions in membrane broadning, that stabilizes plaques furthermore as destroys the living thing medium, necessary to plaque rupture.[48] The MMPs are categorised into opening scleroproteinases that demean fibrillar collagen (MMP-1, -8, -13, and -14), gelatinases that degrade denaturised scleroprotein (MMP-2 and -9), stromelysins to facilitate a broader specificity (MMP-3, -7, -10, and -11), and phagocyte enzyme (MMP-12) to in mainly breaks albuminoid.[49] MMP-2, MMP-8, and MMP-9 are foreseeable as proteases that raise hardening of the arteries plaque rupture and clinical events by degenerating structural parts of the plaque medium.[50,51,52] Their activity is decreased by a group of antagonists named as tissue substance of MMP (TIMPS). whereas TIMP-1 and MMP-9 are connected with cardiovascular mortality, heart failure, or both, they're not connected with continual myocardial infraction.[53] MMP-2 is additionally necessary post-myocardial infraction[54] associated is an freelance detector of all-cause mortality in post-ACS.[55] associate elevated MMP-2 operate in plaques is connected with a accumulated rate following anemia vessel events.[56] In distinction to MMP-2, higher MMP-8 levels within the arteria plaque area unit joined with associate unstable plaque constitution. Elevated MMP-8 levels within the arteria plaque area unit connected with the incidence of a general vas outcome through the follow-up.[57] Newly, Goncalves, et al.[58] establish that the plasma levels of MMP-7 associated -12 area unit high in kind a pair of DM which the higher concentration are connected with additional severe arterial sclerosis and an accumulated prevalence of coronary events.

BIOMARKERS OF INFLAMMATION

HIGH SENSITIVITY REACTIVE PROTEINS (hsCRP)

CRP could be a a part of the pentraxin cluster of innate immunologic response proteins. This can be nonspecific inflammatory biomarker that has wide examined in CVD.[59] CRP by its own mediates atherothrombosis.[60] The Women's Health examination and therefore the Physicians' Health examination, conducted in healthy girls and men, correspondingly, showed associate involvement of CRP and vas measures freelance of more vas risk factors.[61,62] HsCRP that determines lower levels of CRP (< 5mg/L) stratifies volunteers into low, intermediary and elevated risk, therefore those classified as intermediary and high risk may have advantage from antagonistic medical care.[63] in a very meta-detection, peripheral over one lakh sixty thousand volunteers with 1.3 million person-years of follow-up and virtually twenty eight thousand prevalence of CVD events, every variance enhance in hsCRP (log-normalized) was connected with a virtual risk increase of one.37 for CAD (95% CI: one.27–1.48) and 1.55 (95% CI: one.37–1.76) for vas death.[64] To boot, in patients experiencing transcutaneous coronary intervention (PCI), elevated CRP concentration at the time of the procedure are prophetic for 10-year transience and MI.[65] The ecu society of medical specialty (ESC) rules additionally provides hsCRP a category IIb suggestion, stating that hsCRP is also thought-about as a part of refined risk measuring in patients with abnormal or moderate cardiovascular risk profiles.[66] Thus, the understanding of hsCRP results is simple: levels < one mg/L are pleasing and replicate a low general inflammatory condition and lower hardening of the arteries risk; levels involving one and three mg/L signifies moderate vascular risk; levels > 3 mg/L indicate accumulated vascular risk within the circumstance of more risk factors and values that are > ten mg/L would possibly replicate a short-lived contagious method or different severe part response, therefore should be frequent at intervals two to a few weeks. whereas it's direct reference to cardiovascular events and current investigations embody confirmed CRP to be a analyst of cardiovascular events, hsCRP isn't doubtless to be a underlying issue of CVD.[67-69]

GROWTH DIFFERENCIATION 15 (GDF-15)

GDF-15, earlier observed as macrophage-inhibitory cytokine-1, could be a completely different member of the changing growth factor-β protein super cluster and is articulated by activated macrophages.[70] it's connected with cellular aerophilic stress, ischemia, and strain; however, it's unidentified whether or not GDF-15 is causally involved within the pathological procedure resulting in CVD or contains a cellular protecting role.[71,72] Kempf, et al.[73] discovered knockout mice and originate that GDF-15 compete a most significant role in organizing inflammatory cell enrollment by directly move with blood corpuscle integrin activation, consequently inhibiting blood corpuscle seize and extravasation. the implications counsel that GDF-15 act as associate substance of blood corpuscle enrollment within the heart. GDF-15 could be a robust interpreter of all-cause, CVD, furthermore as non-cardiovascular death in community-dwelling aged people, adding up progressive price to standard risk factors and CRP levels, therefore suggesting a basic role within the biological processes connected with aging.[74] A current study has disclosed that temporal alterations of GDF-15 concentrations will increase risk predict in associate aged population.[75] In severe failure (AHF) volunteers listed within the RELAX-AHF study, improved GDF-15 levels were joined with a far better risk of adverse outcomes.[76] The FRISC-II examination, that irregular volunteers with non-ST phase high infarction (NSTEMI) to standard and early invasive methods, found that GDF-15 would possibly predict death or continual MI within the ancient cluster except within the close cluster, that advise that GDF-15 enhances patient assortment for early invasive strategy.[77] The involvement of GDF-15 with CVD, like ACS, steady CAD, and HF, makes it a original capable biomarker for risk measuring, freelance of another recognized risk biomarkers.[78] examination regarding the vas risk stratification of GDF-15 be 43] Wollert, et al.[79] accounted 2 cut-offs for recapitulate in Table.[79] GDF-15. the value of 1200 ng/L was measured as associate optimum cut-off for many in all probability healthy persons, and therefore the value of 1800 ng/L was measured as associate optimum in patients with Non ST-increase acute coronary syndromes (NSTEACS) and for the explanations of risk stratification in ACS patients. Though, GDF-15 is non specific for CVD and has been found to be outstanding in a very assortment of malignancies (prostate, colon, glial). But, promising results from clinical trials propose that GDF-15 could be a probable tool for risk stratification and helpful decision-making.

Table 2: Clinical examination using GDF-15 for CVD risk management.[75-85]

Study intake	*N*	Conclusion	Threshold	Percentage risk
PIVUS study	1016	All give rise to death	Medium (1242ng/L)	1.68
ALPS-AMI	430	All responsible to cause mortality, MI, stoke,or hospitalization due to CHF.	Less than 1221 ng/L, more than 1221ng/L	1.001
PLATO trial	16,876	CV mortality, impulsive MI, and stroke	Quartile (<1145ng/L,>2219ng/L)	1.4
IABP-SHOCK	600	All-cause death	Middle	1.88
Assumed AMI	1247	All cause mortality, acute myocardial infraction	More than 1200ng/L, more than 1800ng/L	19.2, 20.1
NSTE-ACS	1146	Mortality or Non critical MI	Middle	2.4
AtheroGene	1016	Incurable MI, Cardiovascular death	More than 1499ng/L	2.81, 2.67

FIBRINOGEN

Fibrinogen was the first plasma protein, disclosed and delineated within the half of the nineteenth century.[86] factor I is AN severe part supermolecule that is synthesized within the liver, and its current levels will transcend seven mg/mL through acute inflammation. in addition, it's involved in thrombocyte aggregation, epithelium harm, plasma thickness, and plays a essential role within the development of clot. distinguished factor I levels ar connected with AN improved risk of incident CVD. The FSC study value the association of factor I concentrations with the danger of each main tube-shaped structure and non-vascular conclusion supported 154,211 individual vounteers info not together with acknowledged CVD from thirty one prospective examination.[87] The results demonstrate that factor I|clotting factor} concentration be a risk factor for CAD, stroke, and death. within the ERFC study, Kaptoge, et al.[88] Examines info from fifty three prospective examination involving 246,669 participants lacking a history of CVD, additionally it absolutely was determined that the estimation of serum globulin or factor I concentrations was connected with a substantial improvement within the foretelling of vessel events. Estimation of the serum globulin or factor I concentration in humans on AN intermediate risk for a vessel event would possibly assist to stop more events over a decade of ten years for each four hundred to five hundred volunteer screened. Furthermore, factor I consists of 2 sets of 3 peptide chains: Aα, Bβ, and γ and 8-15% flowing factor I in healthy volunteers contains γ chain (γA/γ'). presently an oversized prospective trial showed a positive affiliation of γ' factor I with CAD event, ischemia, peripheral vein malady, HF, and additionally vessel mortality.[89] The examination propose that (γA/γ') factor I may be a casual risk cause for CVD. In vitro as wll as in vivo findings demonstrates that patients with post-AMI, AN overall distinction in

chemical reaction condition and noticeable factor I carbonylation be connected with distorted activity activity and vulnerability of plasmin-induced lysis.[90] These characteristics might contribute to higher approach into the pathophysiology of factor I in severe vessel proceedings. ESC rules on CVD shunning in clinical performance assign factor I assesment as a subpart of the danger estimation in patients with an atypical an moderate vessel risk excluding symptomless low-risk persons.

URIC ACID

Uric acid is end product of purine metabolism in people the inactivation of uricase and therefore the higher concentrations of acid ar thought of to possess gift organic process compensation by defensive against aerobic injury.[91] accrued body fluid acid are hypothesized to contribute to CVD progression, even below the clinical threshold for hypercricemia[92] via rising aerobic stress, prompting epithelium disfunction, along side increasing inflammation. Current studies have demonstrate an freelance positive affiliation among acid and vessel death.[93,94] But, there's still contradictory indication for the results. For example, many epidemiologic examination, comprising prospective, retrospective, cross sectional, and meta-determination, haven't demonstrate AN freelance affiliation between acid and upset.[95,96] In distinction, AN 8-year summarizes study of 90,393 taiwanese specify that hperuricemia be AN freelance risk event of vessel mortality.[97] moreover, the mendalian organization examination accounted that AN higher acid concentration is expounded with sudden cardiac mortality(HR: two.41; 95% CI, 1.16-5.0) no matter typical events.[98] These findings recommend that uric is casually connected with undesirable cardiovascular outcomes, specifically sudden cardiac mortality. Positive affiliation have additionally exhibit between specific population that are at a accrued risk for CVD, like people with established type-2 polygenic disease[99], high blood pressure[100], or a history of coronary artery disease.[101]

BIOMARKERS OF THROMBOCYTE ACTIVATION

LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2 (Lp-PLA2)

Lp-PLA2 may be a related to phospholipase A2 cluster and is additionally recognized as platelet-activating tylhydrolase. it's primarily created by monocytes further as macrophages. Lp-PLA2 is additionally to adapt the surface of lipoprotein particles within the lipoid reaction method, that successively enhances their vulnerability to decomposition.[101] Beyond lipoprotein reaction, Lp-PLA2 is accountable for the discharge of lyso-phosphatidylocholine and rotten fatty acids, that activates the inflammatory cascade. The agglomeration of lyso-phosphatidylcholine and rotten fatty acids within the sub-intimal space boost the advance of the plaque macromolecule core and encourage the alteration of macrophages into foam cells. Lp-PLA2 activity appears to be vital for its involvement toward vulnerable plaques and therefore the incidence of ACS. The West of European country Coronary shunning Study be the primary examination representing AN affiliation between eminent Lp-PLA2 values and vessel events.[102] resultant experimentation confirmed that Lp-PLA2 activity was an freelance detector of CAD and stroke more than typical risk factors within the broad population. In 2012, along the yank and European guideline counseled the assimilation of Lp-PLA2 capability into patients' of cardiovascular risk measurement.[103] Although higher Lp-PLA2 levels are shown to be connected with an elevated cardiovascular risk freelance of more covariates, the widely progressive clinical quality of this biomarker remains vague. in addition, 2 current large-scale irregular assessment didn't show ANy clinical advantage in balanced or unbalanced CAD patients by the utilization of an Lp-PLA2 suppresor.[104,105] These consequences shed doubt regarding the potential effectualness of this biomarker in cardiovascular risk detection. Therefore, more examination are desired to line up the causative operate of Lp-PLA2 in vessel events.

SECREATORY PHOSPHOLIPASE A2 (sPLA2)

The sPLA2 family includes of ten disulfide-rich isoenzymes of low mass, that is that the major cluster of this family of enzymes. they're sPLA2-IB, -IIA, -IIC, -IID, -IIE, -IIF, -III, -V, -X, and -XIIA, and these isoenzymes agonize with a range of biological developments.[106] Away from the sPLA2s, sPLA2-IIA, sPLA2-V, and sPLA2-X are recognized in induration of the arteries injury and cardiac muscle regions that have sustained ischaemic harm.[107,108] This biomarker serves to inflammation and atherogenesis, also concer with platlate activation via prostanoid pathway stimulation and promoting LDL oxidation.[109,110] Observational studies suggested that higher circulating sPLA2-IIA concentrations also sPLA2 function are connected with elevated risk of incident recurring cardiovascular events, (cardiovascular mortality, acute myocardial infraction and stroke).[111,112] Varespladib did not decrease the risk of recurring cardiovascular events and improves the risk of myocardial infraction.[113] Therefore scientific values of measuring sPLA2 concentration are remain unclear.

SOLUBLE CD40 LIGAND (sCD40L)

CD40L is a protein that is primarily expressed on activated T cells belongs to TNF group and is demonstrated in a veritey of cells involving lymphocytes, nerve fibre cells, neutrophils, and macrophages) additionally nonresistant cells (such as animal tissue cells, tube-shaped structure swish muscle cells, and epithelium cells.[117]



Fig. 5: Interaction of CD40L with its receptor CD40 exerting different immune response.CD40 on B cells produces antibodies, these antibodies have different effects in monocytes and macrophages these effects includes production of the inflammatory mediators such as cytokines, chemokines, PGs, COX and causes formation of NO and apoptosis.

The interaction of CD40L through its receptor CD40 is of exacting significance for immunomodulating properties. The surface-expressed CD40L is consequently cleaved over a time of minutes to hours, generating a soluble portion (sCD40L) that's additionally connected with arteriosclerosis beside with plaque instability. severally binding to CD40 and so resulting in its commencement, sCD40L skills to connect receptors within the blood platelet surface, so liable for its stimulation with extra secretion of the soluble kind in a very medium circle of intonation.[117] Two massive, prospective trials (the CAPTURE analysis[118] and the Women's Health examination[119]), according the prognostic importance of sCD40L as a biomarker for distinctive consecutive vas risk equally in patients with CAD and alternatively in healthy people. Recently, the severe Nondisabling vessel assessment (CHANCE) examination examine 3044 consecutive patients and recognized that eminent sCD40L levels severally foretold continual stroke in patients with slight stroke and temporary ischaemic attack.[120] Though, data within the literature concerning the diagnostic accurateness of sCD40L in patients with AMI are disreputable, and several other investigators have established that sCD40L isn't coupled to the likelihood of mortality, MI, or non-fatal continual events.[121] Besides, Liebetrau, et al.[122] ascertained associate degree acute decrease of sCD40L within the setting of early AMI, additionally they think about that a discount in acute blood platelet activation could also be the explanation. extra examination ar required so as to spot an explicit character for sCD40L within the regular assessment of patients with reminiscent of vas ischaemic symptoms.

BIOMARKERS OF NEUROHORMONAL ACTIVTION COPEPTIN

Copeptin, a glycosylated 39-amino-acid amide, may be a C-terminal fraction of the precursor pre-provasopressin (pre-proAVP) is also releases the same amount as AVP. Copeptin is steady and encompasses a half-life of days in plasma, as compared to 5–20 min for AVP.[123] Consequently, copeptin has been recognized as a accountable biomarker for heart diseases additionally a predictor of mortality in situ of AVP. Copeptin is deliberate to be a unique characteristic of the activation of the hypothalamus-pituitary-adrenals axis.[124] intrinsically, copeptin has established main focus in clinical follow up as a marker of cardiovascular events (i.e., AHF, AMI[125], similarly as stroke[126]) and extra-cardiac circumstances (i.e., sepsis[127] and infection[128]). Newly, Tasevska, et al.[128] Ascertained that copeptin would possibly forecast CAD improvement and vas death equally in diabetics and non-diabetics. Volunteers belonging to the highest against the lowest mark of copeptin have a > 70% increased risk of dying from CAD. in addition, Boeckel, et al.[129] originate a vital improvement of copeptin in patients suffering associate degree AMI except an on the spot internal organ discharge into the coronary circulation in AMI. Consequently, whether or not the center similarly contributes to a discharge of copeptin into the blood remains a issue of debate.

Mid-REGINOL-pro-ADRENOMODULLIN (MR-proADM)

Adrenomedullin (ADM), a 52-amino acid ringed vasodiltor amide with C-terminal amidation, was 1st isolated in 1993 originated in tumor cells within the ductless gland.[130] ADM may be a potent vasodilative

manufacture within the ductless gland, tube epithelial tissue cells, the heart, et al in response to physical stretch and specific cytokines. ADM concentration within the heart will increase as a results of pressure and amount overload. it's difficult to measure plasma ADM concentration because of its short half-life and therefore the survival of binding proteins. This amide is ultimately quantified by activity MR-proADM, that is any steady and is made in a very 1:1 magnitude relation with active ADM.[120] Klip, et al.[131] established that MR-proADM may be a capable biomarker associate degreed has robust prophetic value for mortality and morbidity in patients with coronary failure following an AMI and is grater to NT-proBNP in risk detection. Bahrmann, et al.[132] prospectively examines the extrapolative performance of varied biomarkers in unselected geriatric patients (aged eighty one ± six years) within the crisis section, and originate that MR-proADM be the sole detector of caediovascular mortality. MR-proADM is totally coupled with limb pulse pressure and arterial blood vessel intima-media thickness.[133] so, MR-proADM seems as a promising prophetic biomarker for early induration of the arteries plaque enlargement and subclinical CAD. Besides, eminent MR-proADM plasma levels are powerfully connected with typical vas risk factors and CAD.[134] Haaf, et al.[135] indicate that though MR-proADM didn't contain any clinical utility in early AMI identification, it provide prophetic worth for all-cause death. whereas it's promising for deteccting short-run prediction, a lot of knowledge is crucial before MR-proADM is deliberate to be ready for prime-time medical use.[136]

BIOMARKERS OF MUSCLE PATHOLOGY OR STRESS

NATRIURETIC PEPTIDES

The natriuretic peptides are kind of like family of annular peptides concerned in metal and water equilibrium. variety of structurally comparable natriuretic amides are recognized: the atrial natriuretic peptide (ANP), B-type natriuretic amide (BNP), C-type natriurertic amide (CNP), and reptile genus natriuretic amide (DNP).[137,138] Of those, ANP and BNP ar recorded and in the main fashioned within the myocytes of the atria and therefore the ventricles, correspondingly. In circumstances of heart muscle stretch, the stimulation of the BNP factor consequences within the producing and discharge of prohormone, that is braked into the biologically a lot of steady N-terminal pro–B-type symptom amide (NT-proBNP).[139] The ARIC study established that NT-proBNP is severally connected with incidence coronary failure and enhances coronary failure risk identification outside the traditional risk factors, even amongst persons with fleshiness.[140] Furthermore, within the Multi-Ethnic Study of arteriosclerosis (MESA) of 5592 volunteers, the investigator incontestable that amongst symptomless persons of multiple ethnicities, NT-proBNP is associate degree self-acting predictor of incident CAD and CVD on the far side clinical risk factors. A alteration in NT-proBNP may provide extra extrapolative data.[141] The Mid-Regional pro-Atrial symptom amide (MR-proANP) may be a splinter of the A-type symptom amide prohormone that's factory-made by cardiomyocytes in reaction to pressure or fluid overload.[142] the utmost plasma values were originate within the arterial blood vessel and arteria, that is reliable with internal organ producing and reveal chamber pressure or transmural stress. MR-proANP may be a significantly a lot of stable amide as compared to N-ANP and ANP because of the assay epitopes being set within on the proANP moity.[143] abundant kind of like NT-proBNP, MR-proANP is prognostic for associate degree adverse ends up in patients with intensely decompensated HF. within the PRIDE examination, Kaplan–Meier curves additionally incontestable that MRproANP was severally prophetic to mortality intent on four years of follow up, severally or in a very multimarker approach.[144] Karakas, et al.[145]

New experiential that MR-proANP was severally connected with continual vas events following adjustment for recognized risk factors. whereas each NT-proBNP and MR-proANP were evaluated, the end result indicated that MR-proANP didn't provide extra regarding vas risk stratification ar summarized in Table –prophetic data to NT-proBNP within the inhabitants examination. within the prsent European rules, the peptides be thought to be equivalent for the identification of each chronic coronary failure (CHF) and AHF.[146]

SUPPRESSION OF TUMORIGENICITY 2 (ST2)

The ST2 internal organ marker may be a macromolecule biomarker of internal organ stress encoded by IL1RL1 factor. ST2 is connected with interleukin-1 receptor family.



Types of ST2 marker.[147]

Its downstream belongings could involve activation of T-helper kind a pair of (Th2) cells and production of Th2-related cytokines.[148] Assessment of patients with acute heart muscle misdemeanor[149,150], AHF[151], with symptom coronary failure[152] embody according associations involving higher plasma sST2 values and better risk for mortality and nonlethal adverse internal organ events, like aggravation coronary failure, continual heart failure, and stroke. Dieplinger, et al.[153] established that for stable CAD, improved sST2 was additionally associate degree autonomous 9interpreter of semipermanent all-cause mortality and provides complementary extrapolative data to hs-cTnT and NT-proBNP. The city Heart examination investigated a low-

risk inhabitants, and it had been ascertained that sST2 is connected with improved all-cause and vas death.[154] though', it leftovers unclear what the acceptable ST2 higher reference limit for decoding risk in patients with supposed or established ACS would be. knowledge from MERLIN-TIMI thirty six propose that the traditional value of thirty five ng/mL could be acceptable, however it's not once and for all acknowledged whether or not gender-based thresholds should be taken into thought.[154] The recommended cut-off for sST2 in symptom coronary failure is thirty five ng/mL.[155]

Table 3: Examination involving ST2 for cardiovascular risk stratification.[151-160]

Trials	Population	Endpoint	Threshold	% Hazard
STEMI	677	Responsible for death at 30 days and 1 year.	Medium	9.34,3.15
ACS	373	Responsible for death	5-538pg/Ml, 539-3618pg/Ml.	2.1,2.2
LURIC TRIAL	1345	All responsible for death	>24.6.ng/mL	1.39
MERLIN-TIMI 36 Study	6560	Cardiovascular mortality, heart failure	>35ng/mL	1.09
NSTE-ACS	4432	Cardiovascular mortality, heart failure, myocardial infarction, recurring ischemia	<35ng/mL, more than 35ng/mL	2.08,1.19
Acute Heart failure trial	5306	All responsible for death	Median	10.3
Congestive heart failure	876	All cause and cardiovascular death.	Quartile	1.45,1.55

Endothelin-1 (ET-1)

ET1, a 21-amino acid amide, could be a effective vasoconstrictive and pro-fibrotic endocrine that's hid by tube-shaped structure epithelial tissue cells, with the concentrations that associated to tension and arteria pulmonalis pressure.[161] Increased ET-1 is expounded with this movement in medical clinic practices clinical results and 180-day mortaliy in hospitalized patients with acute coronary failure.[162] ET-1 gave further prognostic knowledge that was gradual there to yielded by NT-proBNP.[163] In any case, of neurohormonal instabiliy, the clinical utilization of the endocrine is restricted. The C-terminal phase of adjunct of Endothelin-1 (CTproET1) is that the additional steady variety of ET1 and indirectly quantifies rhe activity of the epithelial tissue system. In each stable CAD and acute heart muscle misdemeanor patients, CT-proET-1 has been incontestable to the connected with cardiovascular mortality and coronary failure autonomous of clinical variables and showed prophetic concentration corresponding to BNP or NT-proBNP.[164,165]

Galectin-3 (Gal3)

Gal3 could be a glycoprotein-restricting, twenty six kDa glycoprotein family supermolecule that's secreted by actuvated cardiac macrophages. it's a essentiall role in pathology through its improvement of body process, Associate in Nursing it shows an inversion of the inducible gas synthase to arginase switch among plaques.[166] because the late, Maiolino, et al.[167] proclaimed that plasma Gal3 will anticipate cardiac mortality in unsound patients referred for coronary X-ray photography. Besides, Lisowska, et al.[168] Demonstrated that Gal-3 was self governing risk issue of CAD incidence, and a Gal-3 values > 8.7 ng/mL was Associate in self governing extrapolative indicator of increased risk of all-cause death in MI patients throughout mid-term follow up. Gal-3 may also have roles that are associated to the inflammatory cascade sequent cardiovascular injury and pathways modifiable cardiovascular ability.[169] previous examination discovered that galectin-3 look is up-regulated in coronary failure and it should be enforced as a biomarker for the identification and prognosis of HF[170,171], in addition, Gal-3 could be a useful biomarker for the treatment of coronary failure in patients with preserved ejection fraction.[172] Elevated Gal-3 levels area unit related to mortality in each AHF and CHF. The analytical odds quantitative relation of Gal-3 in forecast death in CHF patients was 2.36 (95% CI: one.71–3.26) and 2.30 (95% CI: one.76–3.01) in acute heart patients.[173] in addition, Gal-3 was accepted by the U.S.A. Food and Drug Administration (FDA) in 2010 as a brand new marker within the risk stratification of coronary failure. Though, current confirmation doesn't support the only real use of Gal-3 for the prediction assessment of coronary failure.

Neuregulin-1 (NRG-1)

NRG-1 could be a paracrine protein that's unrestricted from epithelial tissue cells and connect to a family of ErbB receptors on nearby cardiac myocytes to prmote cell survival, growth, and preservation.[174] to this point, quite fifteen dissimilar supermolecule merchandise encoded by the NRG-1 cistron are make a case for. NRG-1 beta, is that the most plentiful NRG-1 supermolecule within the cardiovascular system. NRG-1 matter apply its result in an exceedingly paracrine manner via the family of ErbB (ErbB2, ErbB3, ErbB4) aminoalkanoic acid enzyme receptors. a spread of cardiac stimuli, like aerobic stress, ischemia, and exercise, stimulate the expression of NRG-1.[175] so, NRG-1/ErbB4 paracrine sign within the heart and

counsel that this technique is concerned in cardiovascular adaptation to varied types of physiological stress. Higher NRG-1 levels correlative with additional advanced stages of coronary failure and portended a worse prognosis in coronary failure patients with CAD.[176]

In an survillance cohort of patients with stable CAD referred for PCI, current NRG-1 associated indirectly with harshness of CAD, though is additional in patients with stress tests that were positive for ischaemia.[177] Increased body fluid levels of NRG have conjointly been joined with poor outcomes in patients with coronary failure. likewise with NT-proBNP, accrued body fluid levels of NRG is also Associate in Nursing inadequate physiological analysis to vessel injury, and exogenous management of NRG might recover vessel purpose. These findings area unit reliable with the thought that heart muscle NRG-1 is excited in response to ischaemia. The potential of NRG-1 as a valuable biomarker of CVD warrants more studies.

Future of cardiovascular biomarkers

There are huge number of biomarkers, but the function and biochemistry and their clinical utilization is still not fully clear. Hence, it is hard to states a specified conclusions from the recent evidence regarding the mechanism via which a biomarker might affect the prognosis. There is evidence that combination of biomarkers may elevate the accurateness of certain parameters, the optimal combination for treatment of prognosis need to be defined. All biomarkers are work in conjugation with different clinical information including history, physical and different test and radiographic findngs.

Biomarker development

Following are he methods used use to develop biomarkers.



Fig. 6: Vrious technologies used for biomarker development.

REFERENCES

1. Ankur R, Nidhi D, Seema R, A marjeet D, Ashok D, Hyperlipedemia- A deadly pathological condition. Int J Curr Pharm Res., 2012; 4(2): 15-8.
2. Hozawa A. Folsom AR, Sharett AR, et al. Absolute and attributable risks of cardiovascular disease incidence in relation to optimal and brrderline risk factors; Comparison Of African With White Subjects- atherosclerosis risk in Communities Study, Arch Intern Med., 2007; 167: 573-579.
3. Biomarkers Definitions Working G, Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmaol Ther., 2001; 69: 89-95.
4. Smith G. Charles, O' Donnell T. James, the process of novel drug discovery and development: 2nd ed., 2006; 343-345.
5. Fox N. Growdon JH. Biomarkers and Surrogate. Neuro RX., 2004; 1: 181.
6. Ravi Dhingra MD, Ramachandra S. Vasan MD, DM, FACC, FAHA, Bomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers, Trend in cardiovascular medicines, 2016.
7. Prentice RL, Surrogate endpt in clinical trials; definition and operational criteria, stat med., 1998; 8: 431-440.
8. Colbum WA; Optimizing the use of biomarkers surrogate endpoints, and clinical endpoints for more efficient drug development, J Clinn Pharmacol, 2000, 2000; 40: 1419-1427.
9. De Grutola VG, Clax P DeMets DL, Dowing GJ, Ellenberg SS, Friedman L, Gail MH, Prentice R, Wittes J, Zeger SL, Consideration in the evaluation of surrogate endpoints in clinical trials: summary of national institutes of health workshop. Control Clin Trials, 2001; 22.
10. Panju AA, Hemmelgarn BR, Guyatt GH, Simel DL. Is this patient having a myocardial infarction? JAMA, 1998; 280: 1256–1263.
11. Po485-502.pe JH, Aufderheide TP, Ruthazer R, Woolard RH, Feldman JA, Beshansky JR, Griffith

JL, Selker HP. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med., 2000; 342: 1163–1170.
12. Swap CJ, Nagurney JT. Value and limitations of chest pain history in the evaluation of patients with suspected acute coronary syndromes. JAMA, 2005; 294: 2623–2629.
13. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation, 2003; 108: 1664–1672.
14. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Airaksinen KEJ, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation, 2003; 108: 1772–1778.
15. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther., 2001; 69: 89–95.
16. Fox N, Growdon JH. Biomarkers and surrogates. Neuro Rx., 2004; 1: 181.
17. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med., 1989; 8: 431–440.
18. Colburn WA. Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development. J Clin Pharmacol, 2000; 40: 1419–1427.
19. Hoff J, Wehner W, Nambi V. Troponin in cardiovascular disease prevention: updates and future direction. Curr Atheroscler Rep., 2016; 18: 12.
20. Safford MM, Parmar G, Barasch CS, et al. Hospital laboratory reporting may be a barrier to detection of 'microsize' myocardial infarction in the US: an observational study. BMC Health Serv Res., 2013; 13: 162.
21. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J., 2012; 33: 2551–2567.
22. Korley FK, Jaffe AS. Preparing the United States for high-sensitivity cardiac troponin assays. Am Coll Cardiol, 2013; 61: 1753–1758.
23. Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST segment elevation of the European Society of Cardiology (ESC). Eur Heart J., 2016; 37: 267–315.
24. Cullen L, Mueller C, Parsonage WA, et al. Validation of high-sensitivity troponin I in a 2-hour diagnostic strategy to assess 30-day outcomes in emergency department patients with possible acute coronary syndrome. J Am Coll Cardiol, 2013; 62: 1242–1249.
25. Haaf P, Drexler B, Reichlin T, et al. High-sensitivity cardiac troponin in the distinction of acute myocardial infarction from acute cardiac noncoronary artery disease. Circulation, 2012; 126: 31–40.
26. Everett BM, Brooks MM, Vlachos HE, et al. Troponin and cardiac events in stable ischemic heart disease and diabetes. N Engl J Med., 2015; 373: 610–620.
27. Pelsers MM, Hermens WT, Glatz JF. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta, 2005; 352: 15–35.
28. McMahon CG, Lamont JV, Curtin E, et al. Diagnostic accuracy of heart-type fatty acid binding protein for the early diagnosis of acute myocardial infarction. TAm J Emerg Med., 2012; 30: 267–274.
29. Gami BN, Patel DS, Haridas N, et al. Utility of heart-type fatty acid binding protein as a new biochemical marker for the early diagnosis of acute coronary syndrome. J Clin Diagn Res., 2015; 9: Bc22–Bc24.
30. Kabekkodu SP, Mananje SR, Saya RP. A study on the role of heart type fatty acid binding protein in the diagnosis of acute myocardial infarction. J Clin Diagn Res., 2016; 10: Oc07– Oc10.
31. Otaki Y, Watanabe T, Takahashi H, et al. Association of heart-type fatty acid-binding protein with cardiovascular risk factors and all-cause mortality in the general population: the Takahata study. PLoS One., 2014; 9: e94834.
32. Sangiorgi G, Mauriello A, Bonanno E, et al. Pregnancyassociated plasma protein-a is markedly expressed by monocyte-macrophage cells in vulnerable and ruptured carotid atherosclerotic plaques: a link between inflammation and cerebrovascular events. J Am Coll Cardiol, 2006; 47: 2201–2211.

33. Bayes-Genis A, Conover CA, Overgaard MT, et al. Pregnancy- associated plasma protein a as a marker of acute coronary syndromes. N Engl J Med., 2001; 345: 1022–1029.
34. Lund J, Qin QP, Ilva T, et al. Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation, 2003; 108: 1924–1926.
35. Heeschen C, Dimmeler S, Hamm CW, et al. Pregnancyassociated plasma protein-a levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J Am Coll Cardiol, 2005; 45: 229–237.
36. Lund J, Qin QP, Ilva T, et al. Pregnancy-associated plasma protein a: a biomarker in acute ST-elevation myocardial infarction (stemi). Ann Med., 2006; 38: 221–228.
37. Bonaca MP, Scirica BM, Sabatine MS, et al. Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes. J Am Coll Cardiol, 2012; 60: 332–338.
38. Wu XF, Yang M, Qu AJ, et al. Level of pregnancy-associated plasma protein-a correlates with coronary thin-cap fibroatheroma burden in patients with coronary artery disease: novel findings from 3-vessel virtual histology intravascular ultrasound assessment. Medicine, 2016; 95: e2563.
39. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol., 2005; 25: 1102–1111.
40. Yunoki K, Naruko T, Inaba M, et al. Gender-specific correlation between plasma myeloperoxidase levels and serum high-density lipoprotein-associated paraoxonase-1 levels in patients with stable and unstable coronary artery disease. Atherosclerosis, 2013; 231: 308–314.
41. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA, 2001; 286: 2136–2142.
42. Meuwese MC, Stroes ES, Hazen SL, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the epic-norfolk prospective population study. J Am Coll Cardiol, 2007; 50: 159–165.
43. Sawicki M, Sypniewska G, Kozinski M, et al. Diagnostic efficacy of myeloperoxidase for the detection of acute coronary syndromes. Eur J Clin Invest, 2011; 41: 667–671.
44. Tang WH, Tong W, Troughton RW, et al. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol., 2007; 49: 2364–2370.
45. Cavusoglu E, Ruwende C, Eng C, et al. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol., 2007; 99: 1364–1368.
46. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation, 2003; 108: 1440–1445.
47. Nicholls SJ, Tang WH, Brennan D, et al. Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain. Clin Chem., 2011; 57: 1762–1770.
48. Newby AC. Metalloproteinases promote plaque rupture and myocardial infarction: a persuasive concept waiting for clinical translation. Matrix Biol., 2015; 44–46: 157–166.
49. Gu W, Liu W, Yang X, et al. Cutis laxa: analysis of metalloproteinases and extracellular matrix expression by immunohistochemistry and histochemistry. Eur J Dermatol, 2011; 21: 717–721.
50. Molloy KJ, Thompson MM, Jones JL, et al. Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation, 2004; 110: 337–343.
51. Kunte H, Amberger N, Busch MA, et al. Markers of instability in high-risk carotid plaques are reduced by statins. J Vasc Surg, 2008; 47: 513–522.
52. Wang LX, Lu SZ, Zhang WJ, et al. Comparision of high sensitivity C-reactive protein and matrix metalloproteinase 9 in patients with unstable angina between with and without significant coronary artery plaques. Chin Med J (Engl), 2011; 124: 1657–1661.
53. Kelly D, Khan SQ, Thompson M, et al. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J, 2008; 29: 2116–2124.
54. Kelly D, Cockerill G, Ng LL, et al. Plasma matrix metalloproteinase- 9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J., 2007; 28: 711–718.
55. Dhillon OS, Khan SQ, Narayan HK, et al. Matrix metalloproteinase- 2 predicts mortality in patients with acute coronary syndrome. Clin Sci (Lond), 2010; 118: 249–257.
56. Lenti M, Falcinelli E, Pompili M, et al. Matrix metalloproteinase-2 of human carotid atherosclerotic plaques promotes platelet activation. Correlation with ischaemic events. Thromb Haemost, 2014; 111: 1089–1101.
57. Peeters W, Moll FL, Vink A, et al. Collagenase matrix metalloproteinase-8 expressed in atherosclerotic carotid plaques is associated with systemic cardiovascular outcome. Eur Heart J., 2011; 32: 2314–2325.
58. Goncalves I, Bengtsson E, Colhoun HM, et al. Elevated plasma levels of mmp-12 are associated with atherosclerotic burden and symptomatic cardiovascular disease in subjects with type 2

diabetes. Arterioscler Thromb Vasc Biol., 2015; 35: 1723–1731.
59. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol, 2004; 29: 439–493.
60. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation, 2003; 107: 398–404.
61. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med., 2000; 342: 836–843.
62. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med., 1997; 336: 973–979.
63. Jaber BL, Madias NE. C-reactive protein levels and outcomes after statin therapy. N Engl J Med., 2005; 352: 1603–1605.
64. Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet, 2010; 375: 132–140.
65. Oemrawsingh RM, Cheng JM, Akkerhuis KM, et al. High-sensitivity C-reactive protein predicts 10-year cardiovascular outcome after percutaneous coronary intervention. EuroIntervention, 2016; 12: 345–351.
66. Vlachopoulos C, Xaplanteris P, Aboyans V, et al. The roleof vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology working group on peripheral circulation: endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis, 2015; 241: 507–532.
67. Lane T, Wassef N, Poole S, et al. Infusion of pharmaceutical- grade natural human C reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res., 2014; 114: 672–676.
68. Noveck R, Stroes ES, Flaim JD, et al. Effects of an antisense oligonucleotide inhibitor of C-reactive protein synthesis on the endotoxin challenge response in healthy human male volunteers. J Am Heart Assoc, 2014; 3.
69. Elliott P, Chambers JC, Zhang W, et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA, 2009; 302: 37–48.
70. Wiklund FE, Bennet AM, Magnusson PK, et al. Macrophage inhibitory cytokine-1 (mic 1/gdf15): a new marker of all-cause mortality. Aging Cell., 2010; 9: 1057–1064.
71. Wallentin L, Hijazi Z, Andersson U, et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (aristotle) trial. Circulation, 2014; 130: 1847–1858.
72. Wollert KC, Kempf T. Growth differentiation factor 15 in heart failure: an update. Curr Heart Fail Rep., 2012; 9: 337–345.
73. Kempf T, Zarbock A, Widera C, et al. Gdf-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med., 2011; 17: 581–588.
74. Daniels LB, Clopton P, Laughlin GA, et al. Growth-differentiation factor-15 is a robust, independent predictor of 11- year mortality risk in community-dwelling older adults: the Rancho Bernardo Study. Circulation, 2011; 123: 2101–2110.
75. Eggers KM, Kempf T, Larsson A, et al. Evaluation of temporal changes in cardiovascular biomarker concentrations improves risk prediction in an elderly population from the community. Clin Chem., 2016; 62: 485–493.
76. Cotter G, Voors AA, Prescott MF, et al. Growth differentiation factor 15 (gdf-15) in patients admitted for acute heart failure: results from the relax-ahf study. Eur J Heart Fail, 2015; 17: 1133–1143.
77. Wollert KC, Kempf T, Lagerqvist B, et al. Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation, 2007; 116: 1540–1548.
78. Ho JE, Mahajan A, Chen MH, et al. Clinical and genetic correlates of growth differentiation factor 15 in the community. Clin Chem., 2012; 58: 1582–1591.
79. Minamisawa M, Motoki H, Izawa A, et al. Comparison of inflammatory biomarkers in outpatients with prior myocardial infarction. Int Heart J., 2016; 57: 11–17.
80. Hagstrom E, James SK, Bertilsson M, et al. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. Eur Heart J., 2016; 37: 1325–1333.
81. Fuernau G, Poenisch C, Eitel I, et al. Growth-differentiation factor 15 and osteoprotegerin in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the Iabp-shock II-trial. Eur J Heart Fail., 2014; 16: 880–887.
82. Damman P, Kempf T, Windhausen F, et al. Growth-differentiation factor 15 for long-term prognostication in patients with non-ST-elevation acute coronary syndrome: an Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. Int J Cardiol, 2014; 172: 356–363.
83. Widera C, Pencina MJ, Bobadilla M, et al. Incremental prognostic value of biomarkers beyond the Grace (Global Registry of Acute Coronary Events) score and high-sensitivity cardiac troponin t in non-ST-elevation acute coronary syndrome. Clin Chem., 2013; 59: 1497–1505.

84. Schnabel RB, Yin X, Larson MG, et al. Multiple inflammatory biomarkers in relation to cardiovascular events and mortality in the community. Arterioscler Thromb Vasc Biol., 2013; 33: 1728–1733.
85. Wollert KC, Kempf T, Peter T, et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation, 2007; 115: 962–971.
86. Lowe GD. Fibrinogen assays for cardiovascular risk assessment. Clin Chem., 2010; 56: 693–695.
87. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant metaanalysis. JAMA.
88. Kaptoge S, Di Angelantonio E, Pennells L, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med., 2012; 367: 1310–1320.
89. Appiah D, Schreiner PJ, MacLehose RF, et al. Association of plasma gamma' fibrinogen with incident cardiovascular disease: the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb Vasc Biol 2015; 35: 2700–2706.
90. Becatti M, Marcucci R, Bruschi G, et al. Oxidative modification of fibrinogen is associated with altered function and structure in the subacute phase of myocardial infarction. Arterioscler Thromb Vasc Biol., 2014; 34: 1355–1361.
91. Fabbrini E, Serafini M, Colic Baric I, et al. Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes, 2014; 63: 976 981.
92. Jin YL, Zhu T, Xu L, et al. Uric acid levels, even in the normal range, are associated with increased cardiovascular risk: the Guangzhou Biobank Cohort Study. Int J Cardiol, 2013; 168: 2238–2241.
93. Dutta A, Henley W, Pilling LC, et al. Uric acid measurement improves prediction of cardiovascular mortality in later life. J Am Geriatr Soc., 2013; 61: 319–326.
94. Zhao G, Huang L, Song M, et al. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. Atherosclerosis, 2013; 231: 61–68.
95. Fenech G, Rajzbaum G, Mazighi M, et al. Serum uric acid and cardiovascular risk: state of the art and perspectives. Joint Bone Spine, 2014; 81: 392–397.
96. Jee SH, Lee SY, Kim MT. Serum uric acid and risk of death from cancer, cardiovascular disease or all causes in men. Eur J Cardiovasc Prev Rehabil, 2004; 11: 185–191.
97. You L, Liu A, Wuyun G, et al. Prevalence of hyperuricemia and the relationship between serum uric acid and metabolic syndrome in the Asian Mongolian Area. J Atheroscler Thromb, 2014; 21: 355–365.
98. Kleber ME, Delgado G, Grammer TB, et al. Uric acid and cardiovascular events: a mendelian randomization study. J Am Soc Nephrol, 2015; 26: 2831–2838.
99. Resl M, Clodi M, Neuhold S, et al. Serum uric acid is related to cardiovascular events and correlates with n-terminal pro-b- type natriuretic peptide and albuminuria in patients with diabetes mellitus. Diabet Med., 2012; 29: 721–725.
100. Wang JG, Staessen JA, Fagard RH, et al. Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension, 2001; 37: 1069–1074.
101. Burke JE, Dennis EA. Phospholipase a2 biochemistry. Cardiovasc Drugs Ther., 2009; 23: 49–59.
102. Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase a2 as an independent predictorof coronary heart disease. West of Scotland coronary prevention study group. N Engl J Med., 2000; 343: 1148–1155.
103. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J., 2012; 33: 1635–1701.
104. White HD, Held C, Stewart R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med., 2014; 370: 1702–1711.
105. 105 Mullard A. Gsk's darapladib failures dim hopes for anti-inflammatory heart drugs. Nat Rev Drug Discov, 2014; 13:481–482.
106. Stafforini DM, McIntyre TM, Zimmerman GA, et al. Platelet-activating factor acetylhydrolases. J Biol Chem., 1997; 272: 17895–17898.
107. Jonsson-Rylander AC, Lundin S, Rosengren B, et al. Role of secretory phospholipases inatherogenesis. Curr Atheroscler Rep., 2008; 10: 252–259.
108. Menschikowski M, Kasper M, Lattke P, et al. Secretory group ii phospholipase a2 in human atherosclerotic plaques. Atherosclerosis, 1995; 118: 173–181.
109. Rosengren B, Peilot H, Umaerus M, et al. Secretory phospholipase a2 group v: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a western diet. Arterioscler Thromb Vasc Biol., 2006; 26: 1579–1585.
110. Leitinger N, Watson AD, Hama SY, et al. Role of group ii secretory phospholipase a2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids. Arterioscler Thromb Vasc Biol., 1999; 19: 1291–1298.
111. Henderson WR, Jr., Chi EY, Bollinger JG, et al. Importance of group X-secreted phospholipase A2

in allergen-induced airway inflammation and remodeling in a mouse asthma model. J Exp Med., 2007; 204: 865–877.
112. Mallat Z, Benessiano J, Simon T, et al. Circulating secretory phospholipase a2 activity and risk of incident coronary events in healthy men and women: the epic-norfolk study. Arterioscler Thromb Vasc Biol., 2007; 27: 1177–1183.
113. Lind L, Simon T, Johansson L, et al. Circulating levels of secretory- and lipoprotein associated phospholipase a2 activities: relation to atherosclerotic plaques and future all-cause mortality. Eur Heart J., 2012; 33: 2946–2954.
114. Ryu SK, Mallat Z, Benessiano J, et al. Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes. Circulation, 2012; 125: 757–766.
115. Nicholls SJ, Kastelein JJ, Schwartz GG, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA, 2014; 311: 252–262.
116. Nelson MR, Tipney H, Painter JL, et al. The support of human genetic evidence for approved drug indications. Nat Genet, 2015; 47: 856–860.
117. Anand SX, Viles-Gonzalez JF, Badimon JJ, et al. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost, 2003; 90:377–384.
118. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med., 2003; 348: 1104–1111.
119. Schonbeck U, Varo N, Libby P, et al. Soluble CD40L and cardiovascular risk in women. Circulation, 2001; 104: 2266–2268.
120. Li J, Wang Y, Lin J, et al. Soluble cd40l is a useful marker to predict future strokes in patients with minor stroke and transient ischemic attack. Stroke, 2015; 46: 1990–1992.109 Plaikner M, Peer A, Falkensammer G, et al. Lack of association of soluble CD40 ligand with the presence of acute myocardial infarction or ischemic stroke in the emergency department. Clin Chem., 2009; 55: 175–178.
121. Liebetrau C, Hoffmann J, Dorr O, et al. Release kinetics of inflammatory biomarkers in a clinical model of acute myocardial infarction. Circ Res., 2015; 116: 867–875.
122. Bolignano D, Cabassi A, Fiaccadori E, et al. Copeptina (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med., 2014; 52: 1447–1456.
123. Katan M, Morgenthaler N, Widmer I, et al. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett., 2008; 29: 341–346.
124. Sorensen NA, Shah AS, Ojeda FM, et al. High-sensitivity troponin and novel biomarkers for the early diagnosis of non-ST-segment elevation myocardial infarction in patients with atrial fibrillation. Eur Heart J Acute Cardiovasc Care., 2016; 5: 419–427.
125. Greisenegger S, Segal HC, Burgess AI, et al. Copeptin and long-term risk of recurrent vascular events after transient ischemic attack and ischemic stroke: population-based study. Stroke, 2015; 46: 3117–3123.
126. Lee JH, Chan YH, Lai OF, et al. Vasopressin and copeptin levels in children with sepsis and septic shock. Intensive Care Med., 2013; 39: 747–753.
127. Alcoba G, Manzano S, Lacroix L, et al. Proadrenomedullin and copeptin in pediatric pneumonia: a prospective diagnostic accuracy study. BMC Infect Dis., 2015; 15: 347.
128. Tasevska I, Enhorning S, Persson M, et al. Copeptin predicts coronary artery disease cardiovascular and total mortality. Heart, 2016; 102: 127–132.
129. Boeckel JN, Oppermann J, Anadol R, et al. Analyzing the release of copeptin from the heart in acute myocardial infarction using a transcoronary gradient model. Sci Rep., 2016; 6: 20812.
130. Jougasaki M, Burnett JC, Jr. Adrenomedullin: potential in physiology and pathophysiology. Life Sci., 2000; 66: 855–872.
131. Morgenthaler NG, Struck J, Alonso C, et al. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem., 2005; 51: 1823–1829.
132. Klip IT, Voors AA, Anker SD, et al. Prognostic value of mid-regional pro adrenomedullin in patients with heart failure after an acute myocardial infarction. Heart, 2011; 97: 892–898.
133. Bahrmann P, Christ M, Hofner B, et al. Prognostic value of different biomarkers for cardiovascular death in unselected older patients in the emergency department. Eur Heart J Acute Cardiovasc Care, 2016; 5: 568–578.
134. Gottsater M, Ford LB, Ostling G, et al. Adrenomedullin is a marker of carotid plaques and intima-media thickness as well as brachial pulse pressure. J Hypertens, 2013; 31: 1959–1965.
135. Neumann JT, Tzikas S, Funke-Kaiser A, et al. Association of mr-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease. Atherosclerosis, 2013; 228: 451–459.
136. Haaf P, Twerenbold R, Reichlin T, et al. Mid-regional pro-adrenomedullin in the early evaluation of acute chest pain patients. Int J Cardiol, 2013; 168: 1048–1055.

137. Cea LB. Natriuretic peptide family: new aspects. Curr Med Chem Cardiovasc Hematol Agents, 2005; 3: 87–98.
138. Mueller T, Gegenhuber A, Dieplinger B, et al. Long-term stability of endogenous b-type natriuretic peptide (BNP) and amino terminal probnp (NT-PROBNP) in frozen plasma samples. Clin Chem Lab Med., 2004; 42: 942–944.
139. Ndumele CE, Matsushita K, Sang Y, et al. N-terminal pro-brain natriuretic peptide and heart failure risk among individuals with and without obesity: the Atherosclerosis Risk in Communities (ARIC) study. Circulation, 2016; 133: 631–638.
140. Daniels LB, Clopton P, deFilippi CR, et al. Serial measurement of n-terminal pro-b-type natriuretic peptide and cardiac troponin t for cardiovascular disease risk assessment in the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J., 2015; 170: 1170–1183.
141. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med., 1998; 339: 321–328.
142. Ala-Kopsala M, Magga J, Peuhkurinen K, et al. Molecular heterogeneity has a major impact on the measurement of circulating n-terminal fragments of a- and b-type natriuretic peptides. Clin Chem., 2004; 50: 1576–1588.
143. Shah RV, Truong QA, Gaggin HK, et al. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J., 2012; 33: 2197–2205.
144. Karakas M, Jaensch A, Breitling LP, et al. Prognostic value of midregional pro-a-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in patients with stable coronary heart disease followed over 8 years. Clin Chem., 2014; 60: 1441–1449.
145. McMurray JJ, Adamopoulos S, Anker SD, et al. Esc guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the esc. Eur Heart J 2012; 33: 1787–1847.
146. Januzzi JL, Jr. St2 as a cardiovascular risk biomarker: from the bench to the bedside. J Cardiovasc Transl Res., 2013; 6: 493–500.
147. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin- 1-like cytokine that signals via the IL-1 receptor- related protein ST2 and induces T helper type 2-associated cytokines. Immunity, 2005; 23: 479–490.
148. Dhillon OS, Narayan HK, Khan SQ, et al. Pre-discharge risk stratification in unselected stemi: is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers? Int J Cardiol, 2013; 167: 2182–2188.
149. Demyanets S, Speidl WS, Tentzeris I, et al. Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. PLoS One, 2014; 9: e95055.
150. Manzano-Fernandez S, Mueller T, Pascual-Figal D, et al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol., 2011; 107: 259–267.
151. Ky B, French B, McCloskey K, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011; 4: 180–187.
152. Dieplinger B, Egger M, Haltmayer M, et al. Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the ludwigshafen risk and cardiovascular health study. Clin Chem., 2014; 60: 530–540.
153. Chen LQ, de Lemos JA, Das SR, et al. Soluble ST2 is associated with all-cause and cardiovascular mortality in a population- based cohort: the Dallas heart study. Clin Chem., 2013; 59: 536–546.
154. Kohli P, Bonaca MP, Kakkar R, et al. Role of ST2 I non-st-elevation acute coronary syndrome in the merlin-timi 36 trial. Clin Chem., 2012; 58: 257–266.
155. Daniels LB, Bayes-Genis A. Using ST2 in cardiovascular patients: a review. Future Cardiol, 2014; 10: 525–539.
156. O'Malley RG, Bonaca MP, Scirica BM, et al. Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the merlin-timi 36 trial (metabolic efficiency with ranolazine for less ischemia in non ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36). J Am Coll Cardiol, 2014; 63: 1644–1653.
157. Pascual-Figal DA, Manzano-Fernandez S, Boronat M, et al. Soluble st2, high-sensitivity troponin t- and n-terminal pro-b-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail, 2011; 13: 718–725.
158. Lassus J, Gayat E, Mueller C, et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol, 2013; 168: 2186–2194.
159. Bayes-Genis A, de Antonio M, Vila J, et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for longterm heart failure risk stratification: St2 versus galectin-3. J Am Coll Cardiol, 2014; 63: 158–166.
160. Davenport AP, Hyndman KA, Dhaun N, et al. Endothelin. Pharmacol Rev., 2016; 68: 357–418.
161. Perez AL, Grodin JL, Wu Y, et al. Increased mortality with elevated plasma endothelin-1 in

acute heart failure: an ascend- hf biomarker substudy. Eur J Heart Fail, 2016; 18: 290–297.
162. Khan SQ, Dhillon O, Struck J, et al. C-terminal pro-endothelin- 1 offers additional prognostic information in patients after acute myocardial infarction: Leicester Acute Myocardial infarction Peptide (LAMP) study. Am Heart J., 2007; 154: 736–742.
163. Sabatine MS, Morrow DA, de Lemos JA, et al. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation, 2012; 125: 233–240.
164. MacKinnon AC, Liu X, Hadoke PW, et al. Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice. Glycobiology, 2013; 23: 654–663.
165. Maiolino G, Rossitto G, Pedon L, et al. Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease. Arterioscler Thromb Vasc Biol., 2015; 35: 725–732.
166. Lisowska A, Knapp M, Tycinska A, et al. Predictive value of galectin-3 for the occurrence of coronary artery disease and prognosis after myocardial infarction and its association with carotid imt values in these patients: a mid-term prospective cohort study. Atherosclerosis, 2016; 246: 309–317.
167. Dumic J, Dabelic S, Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta, 2006; 1760: 616–635.
168. van Kimmenade RR, Januzzi JL, Jr., Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol, 2006; 48: 1217–1224.
169. Lok DJ, Van Der Meer P, de la Porte PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the deal-hf study. Clin Res Cardiol, 2010; 99: 323–328.
170. Yin QS, Shi B, Dong L, et al. Comparative study of galectin- 3 and b-type natriuretic peptide as biomarkers for the diagnosis of heart failure. J Geriatr Cardiol, 2014; 11: 79–82.
171. Chen YS, Gi WT, Liao TY, et al. Using the galectin-3 test to predict mortality in heart failure patients: a systematic review and meta-analysis. Biomark Med., 2016; 10: 329–342.
172. Lee KF, Simon H, Chen H, et al. Requirement for neuregulin receptor erbb2 in neural and cardiac development. Nature, 1995; 378: 394–398.
173. Kuramochi Y, Cote GM, Guo X, et al. Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbb4 signaling. J Biol Chem., 2004; 279: 51141–51147.
174. Lemmens K, Doggen K, De Keulenaer GW. Role of neuregulin-1/erbb signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation, 2007; 116: 954–960.
175. Geisberg CA, Wang G, Safa RN, et al. Circulating neuregulin- 1beta levels vary according to the angiographic severity of coronary artery disease and ischemia. Coron Artery Dis., 2011; 22: 577–582.
176. Barwari T, Joshi A, Mayr M. Micrornas in cardiovascular disease. J Am Coll Cardiol, 2016; 68: 2577–2584.
177. Wang GK, Zhu JQ, Zhang JT, et al. Circulating microrna: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J., 2010; 31: 659–666.